Establishing a Prognostic Model for Stroke Recovery

February 19, 2026 updated by: National University Hospital, Singapore

Neural Network Reorganization Associated With Upper Limb Motor Recovery in Stroke Patients- Establishing a Prognostic Model and Tailoring Neuromodulation for Rehabilitation

This main aim of the study is to investigate the changes in neurophysiological features after stroke, and its association with upper limb motor recovery, so as to establish a prognostic model for upper limb motor recovery after stroke. The investigators hypothesize that a combination of neurophysiological features measured by transcranial magnetic stimulation (TMS), high density electroencephalography (HD-EEG), functional magnetic resonance imaging (fMRI) and Diffusion Tensor Imaging (DTI) might be used as biomarkers to predict upper limb motor outcomes after stroke. The investigators also hypothesize that non-invasive brain stimulation strategies such as tDCS will more effectively improve motor outcomes as an adjunct to therapy, if tailored according to patient's predicted pattern of neural reorganization.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

This study comprises 2 parts. Study 1 is a longitudinal cohort study to characterize the neurophysiological changes with upper limb motor recovery in stroke patients with moderate to severe upper limb motor function impairment, and its correlation with motor function recovery.

120 stroke subjects within 3 weeks post-stroke will be recruited from National University Hospital (NUH), Alexandra Hospital (AH), and Tan Tock Seng Hospital (TTSH). We will follow changes in cortical activity over time using Transcranial Magnetic Stimulation (TMS), MRI and EEG measures and correlate these with clinical outcome measures at the same time points, to study the interaction between neural excitability and functional outcome.

10 healthy subjects will be needed as control group to compare outcomes obtained from MRI scans.

Outcome measures of brain corticospinal excitability, clinical measures on upper limb motor function and cognitive tests, will be performed 4 times- within 4 weeks, at 3 months, 6 months and 1 year after stroke onset, except for MRI which will not be performed at 1 year after stroke onset.

Subjects from Study 1 whose ARAT (Action Research Arm test) score is < = 42 at 3 months post-stroke will proceed to Study 2. ARAT score < = 42 indicates limited functional capacity and below. The aim of Study 2 is to investigate the efficacy and the neurophysiological effects of 2 types of tDCS protocols in facilitating upper limb motor recovery in patients with significant limitations in upper limb function.

There are a total of 4 groups in Study 2. Subjects who are agreeable for transcranial direct current stimulation (tDCS) will be randomized into 3 groups with 17 subjects in each group, by stratified randomization using Microsoft Excel, according to the lesion location (cortical vs. subcortical), and type of stroke (haemorrhagic vs. ischemic). Subjects who refuse tDCS will be enrolled in the control group without receiving any tDCS stimulation.

  • Group 1 will receive 1 mA anodal tDCS stimulation to the ipsilesional M1 of cortical representation of the affected upper limb;
  • Group 2 to receive 1mA anodal tDCS to the contralesional premotor cortex;
  • Group 3 to receive sham tDCS stimulation with anode placed over the scalp area corresponding to ipsilesional M1.
  • Group 4: Subjects who fulfill the inclusion criteria of Study 2 but refuse tDCS stimulation.

Cathode for all 3 tDCS groups will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training. Subjects in Study 2 will continue with the 6-month and 1 year assessment, as in Study 1.

Study Type

Interventional

Enrollment (Actual)

41

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Singapore, Singapore
        • National University Hospital
      • Singapore, Singapore
        • Alexandra Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

  • Inclusion criteria for stroke patients:

    1. 21-80 years old;
    2. First ever stroke less than 6 weeks;
    3. Moderate to severe upper limb impairment with Manual Muscle Testing (MMT) score on shoulder abduction plus finger extension (SAFE) <5 within the first week post-stroke.
  • Inclusion criteria for healthy subjects:

    1. Age 21-80 years old;
    2. No known medical history.
  • Exclusion criteria for stroke patients:

    1. Pregnancy;
    2. Any metal implants inside the body that are contraindications of MRI scan;
    3. cardiac pacemakers;
    4. History of epilepsy;
    5. Sensorimotor disturbance due to other causes other than stroke;
    6. Claustrophobia;
    7. Uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina;
    8. Major depression and a history of psychotic disorders;
    9. Terminal diagnosis with life expectancy <=1 year.
  • Exclusion criteria for healthy subjects:

    1. Pregnancy;
    2. Any metal implants inside the body that are contraindications of MRI scan;
    3. cardiac pacemakers;
    4. Claustrophobia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Anodal tDCS stimulation to the ipsilesional M1

Participant will receive 1 mA anodal tDCS stimulation to the ipsilesional M1 of cortical representation of the affected upper limb.

Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training.

A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
Experimental: Anodal tDCS to the contralesional premotor cortex
Participant will receive 1mA anodal tDCS to the contralesional premotor cortex. Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training.
A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
Sham Comparator: Sham tDCS

Participant will receive sham tDCS stimulation with anode placed over the scalp area corresponding to ipsilesional M1.

Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training.

A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
No Intervention: Control group
Subjects who fulfill the inclusion criteria of Study 2 but refuse tDCS stimulation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of cortical excitability using Transcranial Magnetic Stimulation (TMS)
Time Frame: Change of the cortical excitability within 4 weeks, at 3 months, 6 months and 1 year after stroke onset
measures of cortical excitability for those without TMS contraindications
Change of the cortical excitability within 4 weeks, at 3 months, 6 months and 1 year after stroke onset
Change of neural excitability using Magnetic resonance imaging (MRI) scan
Time Frame: Change of the neural excitability within 4 weeks, at 3 months, 6 months after stroke onset
Participants will go through one of the following image acquisition procedures 1) a functional MRI scans for brain activity together with motor task. 2) a 3D MPRAGE sequence for brain structure. 3) an advanced multishell high-resolution diffusion MRI for characterizing brain microstructure and extracellular space. 4) a FLAIR scan to measure white matter hyperintensity. Both functional and anatomical image acquisition will be undertaken using but not limited to gradient echo EPI sequence or its modified version.
Change of the neural excitability within 4 weeks, at 3 months, 6 months after stroke onset
Change of neural excitability using electroencephalogram (EEG)
Time Frame: Change of the neural excitability within 4 weeks, at 3 months, 6 months and 1 year after stroke onset
High density EEG (electroencephalogram) evaluation of the electrical activity of the brain
Change of the neural excitability within 4 weeks, at 3 months, 6 months and 1 year after stroke onset
Change of the upper extremity motor function using Fugl-Meyer scale
Time Frame: Change of the upper extremity motor function within 4 weeks, at 3 months, 6 months and 1 year after stroke onset
Upper limb function, Minimum score 0, Maximum score 66, the higher the score the better the upper limb function.
Change of the upper extremity motor function within 4 weeks, at 3 months, 6 months and 1 year after stroke onset
Change of upper extremity performance (coordination, dexterity and functioning) using Action Research Arm Test
Time Frame: Change of upper extremity performance within 4 weeks, at 3 months, 6 months and 1 year after stroke onset
Upper limb function, Minimum score 0, Maximum score 57, the higher the score the better the upper limb function.
Change of upper extremity performance within 4 weeks, at 3 months, 6 months and 1 year after stroke onset
Change of muscle spasticity using Modified Ashworth scale for spasticity (MAS)
Time Frame: Change of muscle spasticity within 4 weeks, at 3 months, 6 months and 1 year after stroke onset
Upper limb function, 6 point scale, Scores range from 0 to 4 (namely 0, 1, 1+, 2, 3 and 4), where lower scores represent normal muscle tone and higher scores represent spasticity or increased resistance to passive movement.
Change of muscle spasticity within 4 weeks, at 3 months, 6 months and 1 year after stroke onset

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of cognitive function using cognitive test
Time Frame: Change of cognitive function within 4 weeks, at 3 months, 6 months and 1 year after stroke onset

The following cognitive test will be performed to assess cognitive function :

  • Digit Span Task
  • Digit Symbol Substitution Task
  • Trail-making test (TMT)-A &B
  • Clock-Drawing Test (CDT)
  • Controlled Oral Word Association Test (COWAT) -animals & FAS
  • Mini-Mental State Exam (MMSE)
  • Rey Auditory Verbal Learning Test (RAVL)
  • Spatial span forward/backward test
  • Visuospatial Paired Associate Learning (VPA)
Change of cognitive function within 4 weeks, at 3 months, 6 months and 1 year after stroke onset

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Effie Chew, MBBS, National University Hospital, Singapore

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Estimated)

July 16, 2026

Study Completion (Estimated)

July 16, 2026

Study Registration Dates

First Submitted

September 13, 2021

First Submitted That Met QC Criteria

April 11, 2022

First Posted (Actual)

April 18, 2022

Study Record Updates

Last Update Posted (Actual)

February 20, 2026

Last Update Submitted That Met QC Criteria

February 19, 2026

Last Verified

September 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke, Acute

Clinical Trials on trancranial magnetic stimulation

Subscribe